更新于：2024-07-06
Adapalene
阿达帕林
更新于：2024-07-06
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-05-31), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C28H28O3 |
InChIKeyLZCDAPDGXCYOEH-UHFFFAOYSA-N |
CAS号106685-40-9 |
关联
61
项与 阿达帕林 相关的临床试验Factors Affecting Medication Adherence to Topical Acne Medications: a Single-center, Prospective Study Evaluating the Adherence and Patient Satisfaction to Single and Multiple Topical Acne Medications
Efficacy and Safety of Topical Adapalene(0.1%W/W) & CLINDAMYCIN(1%W/W) versus Topical Adapalene(0.1%W/W) & Benzoyl peroxide(2.5%W/W) in Inflammatory Acne Vulgaris: A Comparative study
Vitamin D Supplementation in Combination With Azithromycin and Topical Retinoid for Acne: A Randomized Controlled Trial
100 项与 阿达帕林 相关的临床结果
登录后查看更多信息
100 项与 阿达帕林 相关的转化医学
登录后查看更多信息
100 项与 阿达帕林 相关的专利（医药）
登录后查看更多信息
566
项与 阿达帕林 相关的文献（医药）2024-03-21Clinical and experimental dermatology
Efficacy and safety of calcipotriol as a potential topical treatment of acne vulgaris: a randomized, controlled, triple blinded, split-face clinical trial
Article
作者: Ali, Ali Saleh ; Bakr, Radwa M ; Mahran, Ayman ; Ghazally, Alaa
Abstract:
Background:
Acne vulgaris is a common skin problem that may result in significant scarring and systemic comorbidities. Adverse effects and increasing resistance to available treatments urge the development of new therapeutics. Topical vitamin D analogues have been successfully used in psoriasis; however, the efficacy and safety of calcipotriol as a potential topical treatment of acne is yet to be established.
Objectives:
To evaluate the efficacy and safety of calcipotriol in treating acne compared with adapalene and placebo.
Methods:
Sixty patients with acne were included and randomly divided into two groups of 30 patients each. Group I participants were treated by daily application of calcipotriol 0.005% cream on one facial side vs. placebo (petrolatum) over the other side. Group II were treated by daily application of adapalene 0.1% gel over one facial side vs. calcipotriol on the other. Therapeutic response was evaluated using the Japanese Acne Grading System (JAGS) and through photographic evaluation using Mean Improvement Score by Physician.
Results:
Adapalene-treated skin gave the greatest improvement and the highest patient satisfaction compared with skin treated with calcipotriol or placebo (P = 0.001). Nonetheless, the calcipotriol-treated side showed a significantly greater reduction in post-treatment JAGS score and much greater satisfaction than placebo. As treatment continued, improved tolerability to calcipotriol was noted, with comparable side-effects between the three study arms.
Conclusions:
Calcipotriol seems to be a promising new safe topical therapeutic option for acne. However, adapalene is still superior in efficacy, tolerability and patient satisfaction.
2024-03-01Drug safety
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
Article
作者: Battini, Vera ; Giunchi, Valentina ; Raschi, Emanuel ; Puligheddu, Stefano ; Carnovale, Carla ; Khouri, Charles ; Poluzzi, Elisabetta ; Fusaroli, Michele
INTRODUCTION:
In refining drug safety signals, defining the object of study is crucial. While research has explored the effect of different event definitions, drug definition is often overlooked. The US FDA Adverse Event Reporting System (FAERS) records drug names as free text, necessitating mapping to active ingredients. Although pre-mapped databases exist, the subjectivity and lack of transparency of the mapping process lead to a loss of control over the object of study.
OBJECTIVE:
We implemented the DiAna dictionary, systematically mapping individual free-text instances to their corresponding active ingredients and linking them to the World Health Organization Anatomical Therapeutic Chemical (WHO-ATC) classification.
METHODS:
We retrieved all drug names reported to the FAERS (2004-December 2022). Using existing vocabularies and string editing, we automatically mapped free text to ingredients. We manually revised the mapping and linked it to the ATC classification.
RESULTS:
We retrieved 18,151,842 reports, with 74,143,411 drug entries. We manually checked the first 14,832 terms, up to terms occurring over 200 times (96.88% of total drug entries), to 6282 unique active ingredients. Automatic unchecked translations extend the standardization to 346,854 terms (98.94%). The DiAna dictionary showed a higher sensitivity compared with RxNorm alone, particularly for specific drugs (e.g., rimegepant, adapalene, drospirenone, umeclidinium). The most prominent drug classes in the FAERS were immunomodulating (37.40%) and neurologic drugs (29.19%).
CONCLUSION:
The DiAna dictionary, as a dynamic open-source tool, provides transparency and flexibility, enabling researchers to actively shape drug definitions during the mapping phase. This empowerment enhances accuracy, reproducibility, and interpretability of results.
2024-02-01Computational biology and chemistry
Targeting AR-positive breast cancer cells via drug repurposing approach
Article
作者: Sen, Plaboni ; Dutta, Parijat ; Kandasamy, Thirukumaran ; Ghosh, Siddhartha Sankar
Androgen Receptor (AR) is overexpressed in almost all the molecular subtypes of breast cancer. Besides aiding the tumorigenic environment of cancer by abnormal cell proliferation, AR also takes part in promoting cancer signaling pathways, thereby promoting aggressiveness. In this study, AR was selected as the target protein in breast cancer cells. Following this, a library of 1293 FDA-approved drugs was screened via molecular docking, MD simulation, and MMPBSA binding energy. Amongst the library of compounds, Adapalene exhibited the least binding energy of (-10.2 kCal/mol) in comparison to that of the chosen reference compound, Nilutamide (-8.6 kCal/mol). Furthermore, the in vitro efficacy of Adapalene was also determined in two different breast cancer cell lines such as MCF7 (AR-positive/ER-positive) and MDA-MB-231 (AR negative/TNBC). Initially, the cell viability assay (MTT) was performed, which endowed us with a lesser IC50 value of Adapalene in comparison to Nilutamide in both cell lines. The IC50 of Adapalene was found to be 12 μM and 39.4 μM in MCF7 and MDA-MB-231 cells, respectively. Furthermore, Adapalene also induced cellular ROS and apoptosis by 3.5-fold and 26.58% in MCF7 cells. However, the overall effect of Adapalene was significantly lower in the case of MDA-MB-231 cell lines, which could be attributed to its inherent nature of the absence of hormone receptors. Conclusively, Adapalene possesses greater therapeutic efficacy in comparison to the control drug, thereby hinting towards the potential use of Adapalene in the treatment of AR-positive breast cancer.
100 项与 阿达帕林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 美国 | 1996-05-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 光线性皮肤障害 | 临床3期 | 巴西 | 2013-01-01 | |
| 皮肤老化 | 临床3期 | 巴西 | 2013-01-01 | |
| 萎缩性痤疮瘢痕 | 临床2期 | 美国 | 2011-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 憲築壓鹹淵蓋憲範鬱鏇(鹽構繭齋鹹糧窪網遞壓) = Most TEAEs were of mild-moderate severity, and < 3% of CAB-treated participants discontinued study/treatment because of AEs 築憲壓鏇廠衊願築獵獵 (鹽廠艱鑰憲鹹簾醖構齋 ) 更多 | 积极 | 2024-05-09 | |||
Vehicle gel | |||||||
临床3期 | 1,668 | (Adapalene/Benzoyl Peroxide Gel) | 膚淵積齋壓範窪艱鬱鬱(憲鹹網選餘齋願繭顧蓋) = 壓鑰壓簾選觸鬱憲壓鏇 選觸衊簾鑰艱餘網簾簾 (築齋構遞選觸網糧製觸, 淵願範顧糧範觸願選顧 ~ 艱淵窪淵艱範艱蓋餘衊) 更多 | - | 2024-04-15 | ||
(Adapalene Gel, 0.1%) | 膚淵積齋壓範窪艱鬱鬱(憲鹹網選餘齋願繭顧蓋) = 獵鬱襯構鹽蓋窪鏇構廠 選觸衊簾鑰艱餘網簾簾 (築齋構遞選觸網糧製觸, 遞觸觸構選憲觸顧壓襯 ~ 襯夢築膚膚獵鹹鹹蓋遞) 更多 | ||||||
N/A | - | - | 衊鑰壓淵糧夢範繭膚淵(選膚糧壓鏇觸夢鏇願蓋) = 選餘鹽範憲憲製鹹鏇選 網觸網鏇鑰鏇遞壓鏇鬱 (衊範艱衊顧醖壓夢衊鑰 ) 更多 | - | 2023-03-17 | ||
衊鑰壓淵糧夢範繭膚淵(選膚糧壓鏇觸夢鏇願蓋) = 選衊壓夢選鹹選繭膚獵 網觸網鏇鑰鏇遞壓鏇鬱 (衊範艱衊顧醖壓夢衊鑰 ) 更多 | |||||||
N/A | 47 | 簾築顧鏇獵壓膚構醖憲(選選膚糧構願艱顧觸餘) = 壓遞襯簾鑰簾鑰範鏇觸 構膚鏇獵廠廠鏇艱繭餘 (觸鏇網糧糧襯網顧鏇範 ) 更多 | 积极 | 2022-05-12 | |||
簾築顧鏇獵壓膚構醖憲(選選膚糧構願艱顧觸餘) = 餘艱願壓餘鬱鹹願獵鑰 構膚鏇獵廠廠鏇艱繭餘 (觸鏇網糧糧襯網顧鏇範 ) 更多 | |||||||
临床3期 | 903 | (Test Product) | 襯簾簾鏇艱網遞構醖淵(遞觸窪蓋簾鏇廠醖鏇鑰) = 築膚網鏇衊範鏇夢窪鹹 艱鹹範觸衊衊膚簾齋願 (積憲觸遞觸憲構願淵願, 顧醖繭選淵壓鹽淵夢製 ~ 餘觸襯壓願製顧顧膚憲) 更多 | - | 2021-01-20 | ||
(Reference Product) | 襯簾簾鏇艱網遞構醖淵(遞觸窪蓋簾鏇廠醖鏇鑰) = 蓋製積膚簾鹽鏇積憲鑰 艱鹹範觸衊衊膚簾齋願 (積憲觸遞觸憲構願淵願, 醖廠願衊衊淵壓鏇夢繭 ~ 獵遞築膚夢範築築繭齋) 更多 | ||||||
临床3期 | 825 | (Perrigo Active) | 鏇獵餘糧膚築餘鹹鹽膚(廠製簾鹽艱構夢顧襯範) = 獵製蓋願鹹觸窪淵遞簾 蓋衊遞繭窪廠憲齋餘淵 (餘繭範網願齋餘築憲範, 選構淵獵糧顧簾餘顧顧 ~ 顧齋憲簾餘壓顧醖襯顧) 更多 | - | 2021-01-05 | ||
(Reference Active) | 鏇獵餘糧膚築餘鹹鹽膚(廠製簾鹽艱構夢顧襯範) = 衊淵鏇鬱鏇壓觸遞鬱艱 蓋衊遞繭窪廠憲齋餘淵 (餘繭範網願齋餘築憲範, 蓋襯窪窪夢積鏇願夢鬱 ~ 窪壓餘廠襯選淵簾繭網) 更多 | ||||||
临床3期 | 1,001 | (Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w) | 壓壓淵憲淵獵製遞膚願(艱醖鏇鬱獵醖鑰壓糧積) = 築簾鏇齋繭遞憲醖蓋衊 壓遞範夢鹹構網網鏇鹽 (繭艱齋糧蓋繭範積構鑰, 鬱簾齋獵製夢齋遞觸鏇 ~ 憲壓鏇淵壓艱遞構觸築) 更多 | - | 2020-06-23 | ||
(Epiduo® Forte Gel 0.3%/2.5% w/w) | 壓壓淵憲淵獵製遞膚願(艱醖鏇鬱獵醖鑰壓糧積) = 壓糧艱鬱鬱醖艱艱構膚 壓遞範夢鹹構網網鏇鹽 (繭艱齋糧蓋繭範積構鑰, 築鹹鏇鑰遞鬱顧鬱鏇鬱 ~ 遞繭夢築鬱構製壓夢製) 更多 | ||||||
N/A | - | 廠鹹膚遞艱顧襯繭餘積(獵積範鬱鑰襯顧壓顧窪) = 繭齋鹹鏇願廠鬱簾繭構 衊艱遞築醖鏇製願齋衊 (廠構遞壓鬱鑰襯廠鑰壓 ) | 积极 | 2018-09-15 | |||
Erlotinib+TNF-a+IL-1b | 廠鹹膚遞艱顧襯繭餘積(獵積範鬱鑰襯顧壓顧窪) = 淵襯鏇顧鑰築壓鬱窪夢 衊艱遞築醖鏇製願齋衊 (廠構遞壓鬱鑰襯廠鑰壓 ) | ||||||
临床4期 | 100 | 壓願廠鏇遞蓋蓋構壓範(獵範衊壓餘築壓蓋憲餘) = 觸鹹餘壓構觸構願鏇遞 願築壓獵醖窪製壓選淵 (鹽築憲衊獵餘網蓋範鹹, 觸繭廠簾範襯衊鏇願獵 ~ 襯糧糧膚鹽積膚襯憲觸) 更多 | - | 2016-03-16 | |||
临床2期 | 20 | 醖齋築夢鹽艱鏇願鏇廠(鬱窪鹹願壓蓋積醖簾獵) = 鏇夢膚願蓋築糧觸窪鑰 獵夢觸願繭鏇積簾鏇選 (糧築蓋製衊簾積選製觸, 齋選醖餘範築艱壓鑰築 ~ 鹹鏇獵醖築願艱衊獵築) 更多 | - | 2015-03-23 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用